In vivo kinetic approach reveals slow SOD1 turnover in the CNS
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Therapeutic strategies that target disease-associated transcripts are being developed for a variety of neurodegenerative syndromes. Protein levels change as a function of their half-life, a property that critically influences the timing and application of therapeutics. In addition, both protein kinetics and concentration may play important roles in neurodegeneration; therefore, it is essential to understand in vivo protein kinetics, including half-life. Here, we applied a stable isotope-labeling technique in combination with mass spectrometric detection and determined the in vivo kinetics of superoxide dismutase 1 (SOD1), mutation of which causes amyotrophic lateral sclerosis. Application of this method to human SOD1-expressing rats demonstrated that SOD1 is a long-lived protein, with a similar half-life in both the cerebral spinal fluid (CSF) and the CNS. Additionally, in these animals, the half-life of SOD1 was longest in the CNS when compared with other tissues. Evaluation of this method in human subjects demonstrated successful incorporation of the isotope label in the CSF and confirmed that SOD1 is a long-lived protein in the CSF of healthy individuals. Together, the results of this study provide important insight into SOD1 kinetics and support application of this technique to the design and implementation of clinical trials that target long-lived CNS proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Self-citationHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617 · cited 2×
“Recent work by our group using antisense oligonucleotides (ASOs) against SOD1, a gene responsible for 20% of familial ALS cases, has shown great promise in animal models and has recently completed a phase I clinical trial (17).”
BackgroundSelf-citationHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationAutophagy induction enhances TDP43 turnover and survival in neuronal ALS models
Barmada, S. J., Serio, A., Arjun, A., Bilican, B., Daub, A., Ando, D. M., Tsvetkov, A., Pleiss, M., Li, X., Peisach, D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1563 · Cited by 431 · cited 1×
“Consistent with this, in primary culture, slow protein turnover correlates with susceptibility to toxicity (33, 34).”
BackgroundAnalysis of proteome dynamics in the mouse brain
Price, J. C., Guan, S., Burlingame, A., Prusiner, S. B., & Ghaemmaghami, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006551107 · Cited by 357
Extremely long-lived nuclear pore proteins in the rat brain
Savas, J. N., Toyama, B. H., Xu, T., Yates, J. R., & Hetzer, M. W. (2012) · Science · doi:10.1126/science.1217421 · Cited by 335 · cited 1×
“Indeed, global proteomics approaches using stable isotopes have shown that brain proteins possess a slow turnover rate, even if identical proteins or protein complexes are compared between tissues (4, 32).”
BackgroundA γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Self-citationParise, G., Mihic, S., MacLennan, D., Yarasheski, K. E., & Tarnopolsky, M. A. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.3.1041 · Cited by 236 · cited 1×
“The samples were then dried under vacuum and processed for GC-MS analysis as described previously (40).”
MethodSelf-citationIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
Self-citationProteostasis of polyglutamine varies among neurons and predicts neurodegeneration
Tsvetkov, A. S., Arrasate, M., Barmada, S., Ando, D. M., Sharma, P., Shaby, B. A., & Finkbeiner, S. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1308 · Cited by 178
Antisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164 · cited 1×
“Determination of human SOD1 turnover in the CSF has important implications for understanding SOD1 biology in ALS and for biomarker development and monitoring therapy in patients treated with SOD1 ASOs (17, 22, 31).”
BackgroundSelf-citation
Cited by
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586
“In a recent SILK study focused on another CNS protein with a long half-life, superoxide dismutase 1 (SOD1) (Crisp et al., 2015), six healthy participants were orally administered (13)C6-leucine and analyzed by using the SILK method for SOD1 (Figure 3A).”
Self-citationPhase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565
Self-citationNeurofilaments: neurobiological foundations for biomarker applications
Gafson, A. R., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J.-P., Kuhle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 325
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., Schoch, K. M., Hoye, M. L., Shabsovich, M., Sun, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99081 · Cited by 279
“The ASO SOD1 trial in humans with SOD1 ALS is directly on target and the pharmacodynamic marker, SOD1 in the CSF, has been clearly defined (26).”
BackgroundSelf-citation
Metadata
- Authors
- Crisp, M. J., Mawuenyega, K. G., Patterson, B. W., Reddy, N. C., Chott, R., Self, W. K., Weihl, C. C., Jockel-Balsarotti, J., Varadhachary, A. S., Bucelli, R. C., Yarasheski, K. E., Bateman, R. J., & Miller, T. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-06-15
- Volume
- 125
- Issue
- 7
- Pages
- 2772-2780
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1929098576
- Cited by
- 59
- References
- 13
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.